$0.9800
0.043.98%
At close: -
$0.9770
-0.00300-0.31%
After Hours: 7:59 PM EDT
Comments
Loading...
Immunic Analyst Ratings and Price Targets | NASDAQ:IMUX | Benzinga
Immunic Inc has a consensus price target of $15.09 based on the ratings of 12 analysts. The high is $35 issued by Aegis Capital on August 8, 2022. The low is $5 issued by Leerink Partners on September 9, 2024. The 3 most-recent analyst ratings were released by B. Riley Securities, HC Wainwright & Co., and D. Boral Capital on April 16, 2025, April 15, 2025, and April 10, 2025, respectively. With an average price target of $11 between B. Riley Securities, HC Wainwright & Co., and D. Boral Capital, there's an implied 1025.90% upside for Immunic Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B. Riley Securities
HC Wainwright & Co.
D. Boral Capital
EF Hutton
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Immunic
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/16/2025 | Buy Now | 514.12% | B. Riley Securities | William Woods22% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 04/15/2025 | Buy Now | 923.54% | HC Wainwright & Co. | Matthew Caufield36% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2025 | Buy Now | 1640.02% | D. Boral Capital | Jason Kolbert42% | $17 → $17 | Maintains | Buy | Get Alert |
| 04/01/2025 | Buy Now | 1640.02% | D. Boral Capital | Jason Kolbert42% | $17 → $17 | Maintains | Buy | Get Alert |
| 03/25/2025 | Buy Now | — | William Blair | Myles Minter42% | — | Initiates | → Outperform | Get Alert |
| 02/26/2025 | Buy Now | 1640.02% | D. Boral Capital | Jason Kolbert42% | $17 → $17 | Maintains | Buy | Get Alert |
| 02/21/2025 | Buy Now | 923.54% | HC Wainwright & Co. | Matthew Caufield36% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2025 | Buy Now | 1640.02% | D. Boral Capital | Jason Kolbert42% | $17 → $17 | Maintains | Buy | Get Alert |
| 01/07/2025 | Buy Now | 1640.02% | D. Boral Capital | Jason Kolbert42% | $17 → $17 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 923.54% | HC Wainwright & Co. | Matthew Caufield36% | → $10 | Initiates | → Buy | Get Alert |
| 11/07/2024 | Buy Now | 1640.02% | EF Hutton | Jason Kolbert42% | $17 → $17 | Maintains | Buy | Get Alert |
| 10/22/2024 | Buy Now | 1640.02% | EF Hutton | Jason Kolbert42% | $17 → $17 | Maintains | Buy | Get Alert |
| 09/18/2024 | Buy Now | 1640.02% | EF Hutton | Jason Kolbert42% | $17 → $17 | Maintains | Buy | Get Alert |
| 09/16/2024 | Buy Now | 1640.02% | EF Hutton | Jason Kolbert42% | → $17 | Initiates | → Buy | Get Alert |
| 09/09/2024 | Buy Now | 411.77% | Leerink Partners | Faisal Khurshid30% | → $5 | Assumes | → Outperform | Get Alert |
| 08/27/2024 | Buy Now | 514.12% | B. Riley Securities | William Woods22% | → $6 | Initiates | → Buy | Get Alert |
| 07/16/2024 | Buy Now | 2765.92% | Piper Sandler | Yasmeen Rahimi55% | $28 → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 04/05/2024 | Buy Now | 923.54% | Brookline Capital | Tyler Bussian23% | → $10 | Initiates | → Buy | Get Alert |
| 10/10/2023 | Buy Now | 616.48% | Wedbush | Andreas Argyrides69% | $5 → $7 | Maintains | Outperform | Get Alert |
| 07/27/2023 | Buy Now | 411.77% | Wedbush | Andreas Argyrides69% | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 01/31/2023 | Buy Now | 411.77% | Wedbush | Andreas Argyrides69% | → $5 | Assumes | → Outperform | Get Alert |
| 10/21/2022 | Buy Now | 411.77% | SVB Leerink | Thomas Smith33% | $9 → $5 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/19/2022 | Buy Now | 2561.21% | HC Wainwright & Co. | Gobind Singh20% | → $26 | Assumes | → Buy | Get Alert |
| 08/08/2022 | Buy Now | 3482.4% | Aegis Capital | Nathan Weinstein31% | $40 → $35 | Maintains | Buy | Get Alert |
| 06/03/2022 | Buy Now | 821.19% | SVB Leerink | Thomas Smith33% | $45 → $9 | Maintains | Outperform | Get Alert |
| 05/18/2022 | Buy Now | 3891.81% | Piper Sandler | Yasmeen Rahimi55% | $71 → $39 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Immunic (IMUX) stock?
The latest price target for Immunic (NASDAQ:IMUX) was reported by B. Riley Securities on April 16, 2025. The analyst firm set a price target for $6.00 expecting IMUX to rise to within 12 months (a possible 514.12% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunic (IMUX)?
The latest analyst rating for Immunic (NASDAQ:IMUX) was provided by B. Riley Securities, and Immunic reiterated their buy rating.
When was the last upgrade for Immunic (IMUX)?
There is no last upgrade for Immunic
When was the last downgrade for Immunic (IMUX)?
The last downgrade for Immunic Inc happened on October 21, 2022 when SVB Leerink changed their price target from $9 to $5 for Immunic Inc.
When is the next analyst rating going to be posted or updated for Immunic (IMUX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on April 16, 2025 so you should expect the next rating to be made available sometime around April 16, 2026.
Is the Analyst Rating Immunic (IMUX) correct?
While ratings are subjective and will change, the latest Immunic (IMUX) rating was a reiterated with a price target of $6.00 to $6.00. The current price Immunic (IMUX) is trading at is $0.98, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
